Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival—prospective interventional study

BACKGROUND: No chemotherapeutic agents have been standardised for transarterial chemoembolisation (TACE). In particular, doxorubicin has no defined optimal dosage in TACE procedures. We compared low versus currently used dose of doxorubicin for TACE in patients with hepatocellular carcinoma (HCC) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bessar, Ahmed A., Farag, Ahmed, Abdel Monem, Sameh M., Wadea, Fady M., Shaker, Shady E., Ebada, Mahmoud Ahmed, Bessar, Manar A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921261/
https://www.ncbi.nlm.nih.gov/pubmed/33649930
http://dx.doi.org/10.1186/s41747-021-00204-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921261/
https://www.ncbi.nlm.nih.gov/pubmed/33649930
http://dx.doi.org/10.1186/s41747-021-00204-6

Ejemplares similares